These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15373983)

  • 1. [Primary intestinal lymphangiectasia: effectiveness of treatment with slow-release octreotide].
    Balboa A; Perelló A; Mearin F
    Med Clin (Barc); 2004 Sep; 123(8):319. PubMed ID: 15373983
    [No Abstract]   [Full Text] [Related]  

  • 2. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide.
    Filik L; Oguz P; Koksal A; Koklu S; Sahin B
    Dig Liver Dis; 2004 Oct; 36(10):687-90. PubMed ID: 15506669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I intestinal lymphangiectasia treated successfully with slow-release octreotide.
    Klingenberg RD; Homann N; Ludwig D
    Dig Dis Sci; 2003 Aug; 48(8):1506-9. PubMed ID: 12924644
    [No Abstract]   [Full Text] [Related]  

  • 4. Octreotide in the treatment of intestinal lymphangiectasia.
    Ballinger AB; Farthing MJ
    Eur J Gastroenterol Hepatol; 1998 Aug; 10(8):699-702. PubMed ID: 9744700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the objectives of treatment for intestinal lymphangiectasia?
    Takahashi H; Imai K
    J Gastroenterol; 2001 Feb; 36(2):137-8. PubMed ID: 11227672
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary intestinal lymphangiectasia successfully treated with octreotide.
    Kuroiwa G; Takayama T; Sato Y; Takahashi Y; Fujita T; Nobuoka A; Kukitsu T; Kato J; Sakamaki S; Niitsu Y
    J Gastroenterol; 2001 Feb; 36(2):129-32. PubMed ID: 11227670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide management of intestinal lymphangiectasia in a teenage heart transplant patient.
    Altit G; Patel H; Morinville VD
    J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):824-7. PubMed ID: 21768882
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?
    Sari S; Baris Z; Dalgic B
    J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):454-7. PubMed ID: 20512058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide in intestinal lymphangiectasia: lack of a clinical response and failure to alter lymphatic function in a guinea pig model.
    Makhija S; von der Weid PY; Meddings J; Urbanski SJ; Beck PL
    Can J Gastroenterol; 2004 Nov; 18(11):681-5. PubMed ID: 15565209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to treat an extensive form of primary intestinal lymphangiectasia?
    Troskot R; Jurčić D; Bilić A; Gomerčić Palčić M; Težak S; Brajković I
    World J Gastroenterol; 2015 Jun; 21(23):7320-5. PubMed ID: 26109821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.
    Lee HL; Han DS; Kim JB; Jeon YC; Sohn JH; Hahm JS
    J Korean Med Sci; 2004 Jun; 19(3):466-9. PubMed ID: 15201518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory primary intestinal lymphangiectasia effectively managed with subcutaneous octreotide.
    Halim A; Youd P; Thorpe J; Halim I
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33837021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menetrier's disease treated with octreotide long-acting release.
    Green BT; Branch MS
    Gastrointest Endosc; 2004 Dec; 60(6):1028-9. PubMed ID: 15605031
    [No Abstract]   [Full Text] [Related]  

  • 14. Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature.
    Kwon Y; Kim ES; Choe YH; Kim MJ
    BMC Pediatr; 2021 Jan; 21(1):21. PubMed ID: 33407260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy.
    MacLean JE; Cohen E; Weinstein M
    Pediatrics; 2002 Jun; 109(6):1177-80. PubMed ID: 12042562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C; Galeazzi G
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long acting release-octreotide as "rescue" therapy to control angiodysplasia bleeding: A retrospective study of 98 cases.
    Nardone G; Compare D; Scarpignato C; Rocco A
    Dig Liver Dis; 2014 Aug; 46(8):688-94. PubMed ID: 24893688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: Cost-effectiveness study.
    Klímová K; Padilla-Suárez C; Giménez-Manzorro Á; Pajares-Díaz JA; Clemente-Ricote G; Hernando-Alonso A
    Rev Esp Enferm Dig; 2015 Feb; 107(2):79-88. PubMed ID: 25659389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal lymphangiectasia and antiplasmin therapy.
    Cohen SA; Diuguid DL; Whitlock RT; Holt PR
    Gastroenterology; 1992 Jun; 102(6):2193. PubMed ID: 1587455
    [No Abstract]   [Full Text] [Related]  

  • 20. Octreotide therapy in dumping syndrome: Analysis of long-term results.
    Didden P; Penning C; Masclee AA
    Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.